Market closed

Allakos/$ALLK

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Allakos

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Ticker

$ALLK

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Carlos, United States

Employees

131

Website

www.allakos.com

Allakos Metrics

BasicAdvanced

$77M

-

-$2.02

1.02 -

Price and volume

Market cap

$77M

Beta

1.02

52-week high

$1.69

52-week low

$0.54

Average daily volume

377K

Financial strength

Current ratio

6.079

Quick ratio

5.802

Long term debt to equity

49.091

Total debt to equity

49.091

Management effectiveness

Return on assets (TTM)

-48.75%

Return on equity (TTM)

-121.68%

Valuation

Price to book

1.06

Price to tangible book (TTM)

1.06

Price to free cash flow (TTM)

-0.724

Growth

Earnings per share change (TTM)

4.94%

3-year earnings per share growth (CAGR)

-21.21%

What the Analysts think about Allakos

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Allakos stock.

Allakos Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Allakos Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Allakos News

AllArticlesVideos

Allakos Runs Up Into A Near-Term Catalyst

Seeking Alpha·2 months ago

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALLK

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Allakos stock?

Allakos (ALLK) has a market cap of $77M as of January 15, 2025.

What is the P/E ratio for Allakos stock?

The price to earnings (P/E) ratio for Allakos (ALLK) stock is 0 as of January 15, 2025.

Does Allakos stock pay dividends?

No, Allakos (ALLK) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Allakos dividend payment date?

Allakos (ALLK) stock does not pay dividends to its shareholders.

What is the beta indicator for Allakos?

Allakos (ALLK) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.